全文获取类型
收费全文 | 4680篇 |
免费 | 279篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 108篇 |
妇产科学 | 131篇 |
基础医学 | 460篇 |
口腔科学 | 111篇 |
临床医学 | 340篇 |
内科学 | 1147篇 |
皮肤病学 | 52篇 |
神经病学 | 179篇 |
特种医学 | 201篇 |
外国民族医学 | 1篇 |
外科学 | 883篇 |
综合类 | 124篇 |
一般理论 | 3篇 |
预防医学 | 285篇 |
眼科学 | 140篇 |
药学 | 413篇 |
中国医学 | 16篇 |
肿瘤学 | 368篇 |
出版年
2023年 | 49篇 |
2022年 | 49篇 |
2021年 | 220篇 |
2020年 | 120篇 |
2019年 | 155篇 |
2018年 | 208篇 |
2017年 | 122篇 |
2016年 | 113篇 |
2015年 | 141篇 |
2014年 | 192篇 |
2013年 | 235篇 |
2012年 | 356篇 |
2011年 | 343篇 |
2010年 | 227篇 |
2009年 | 186篇 |
2008年 | 270篇 |
2007年 | 279篇 |
2006年 | 247篇 |
2005年 | 253篇 |
2004年 | 170篇 |
2003年 | 166篇 |
2002年 | 162篇 |
2001年 | 71篇 |
2000年 | 81篇 |
1999年 | 52篇 |
1998年 | 24篇 |
1997年 | 18篇 |
1996年 | 15篇 |
1995年 | 17篇 |
1994年 | 12篇 |
1993年 | 21篇 |
1992年 | 44篇 |
1991年 | 51篇 |
1990年 | 35篇 |
1989年 | 26篇 |
1988年 | 27篇 |
1987年 | 19篇 |
1986年 | 29篇 |
1985年 | 13篇 |
1984年 | 19篇 |
1983年 | 15篇 |
1979年 | 8篇 |
1978年 | 9篇 |
1977年 | 14篇 |
1976年 | 7篇 |
1975年 | 8篇 |
1974年 | 15篇 |
1970年 | 11篇 |
1969年 | 11篇 |
1968年 | 9篇 |
排序方式: 共有4989条查询结果,搜索用时 46 毫秒
1.
2.
Hassona Shahd M. Saad Entsar A. Kiwan Hala A. Hassanien Mohamed M. 《Investigational new drugs》2022,40(4):681-689
Investigational New Drugs - Although many cancer drugs are clinically approved, they still suffer from no adequate efficiency or drug resistance, or bad side effects. Therefore, developing safer... 相似文献
3.
4.
Marco Bandini Sebastiano Nazzani Michele Marchioni Felix Preisser Zhe Tian Marco Moschini Firas Abdollah Nazareno Suardi Markus Graefen Francesco Montorsi Shahrokh F. Shariat Fred Saad Alberto Briganti Pierre I. Karakiewicz 《Clinical genitourinary cancer》2019,17(1):72-78.e4
Background
The rate of noninterventional treatment (NIT) in prostate cancer (PCa) active surveillance (AS) candidates is on the rise. However, contemporary data are unavailable. We described community-based NIT rates within 16 Surveillance Epidemiology and End Results (SEER) registries between 2010 and 2014.Patients and Methods
We identified 23,360 PCa patients who fulfilled the University of California San Francisco AS criteria (prostate-specific antigen [PSA] < 10 ng/mL, clinical T stage ≤ T2a, Gleason score ≤ 6, and positive cores < 33%). Annual NIT rates as well as patient distribution according to PSA, age, number of positive cores, and clinical T stage were studied. Multivariable logistic regression analysis tested NIT predictors.Results
Between 2010 and 2014, the NIT rate increased from 30.2% to 57.5% (P = .004). Within 16 SEER registries, NIT rates ranged from 25.9% to 62%. NIT rate increased uniformly within all examined registries. Of patient and tumor characteristics (PSA > 4 ng/mL, cT2a and > 1 positive core) only the proportion of NIT patients aged < 65 years increased over time from 47.3% to 53.2% (P = .03). By multivariable logistic regression analysis predicting NIT rate, older age (odd ratio [OR] = 1.05), more contemporary year of diagnosis (OR = 1.41), and being unmarried (OR = 1.45) and uninsured (OR = 2.41) were independent predictors.Conclusion
The NIT rate has markedly increased across all examined SEER registries. Nonetheless, important differences distinguish those who received high-end NIT from low-end NIT. PCa characteristics of NIT patients remained unchanged over time. However, in addition to geographical differences in NIT rates, patient characteristics such as age, marital status, and insurance status represent potential NIT access barriers. 相似文献5.
6.
Traumatic brain injury (TBI) is the leading cause of trauma-related death and disability in children worldwide. The outcome from TBI can be improved by early aggressive management of oxygenation and blood pressure. There is evidence to suggest that adhering to guidelines when managing these patients can have a positive effect on the outcomes. In this article we review the general supportive and targeted neuroprotective measures that are outlined in international paediatric guidelines and are most widely used in the critical care management of patients with TBI; we further review how these measures can influence the underlying evolving pathophysiology in these patients. The aim of critical care management of patients with TBI is to prevent or limit secondary brain injury by optimizing cerebral perfusion and oxygenation to improve survival and clinical outcomes. We also discuss how to monitor patients with traumatic brain injury on the paediatric intensive care unit and we give a practical approach on how to respond to deteriorating patients and to the complications arising during the course of their management. 相似文献
7.
Rebecca Robillard Karianne Dion Marie‐Helene Pennestri Elizaveta Solomonova Elliott Lee Mysa Saad Anthony Murkar Roger Godbout Jodi D. Edwards Lena Quilty Alexander R. Daros Raj Bhatla Tetyana Kendzerska 《Journal of sleep research》2021,30(1):e13231
This study aimed to evaluate changes in sleep during the COVID‐19 outbreak, and used data‐driven approaches to identify distinct profiles of changes in sleep‐related behaviours. Demographic, behavioural and psychological factors associated with sleep changes were also investigated. An online population survey assessing sleep and mental health was distributed between 3 April and 24 June 2020. Retrospective questions were used to estimate temporal changes from before to during the outbreak. In 5,525 Canadian respondents (67.1% females, 16–95 years old: Mean ± SD = 55.6 ± 16.3 years), wake‐up times were significantly delayed relative to pre‐outbreak estimates (p < .001, = 0.04). Occurrences of clinically meaningful sleep difficulties significantly increased from 36.0% before the outbreak to 50.5% during the outbreak (all p < .001, g ≥ 0.27). Three subgroups with distinct profiles of changes in sleep behaviours were identified: “Reduced Time in Bed”, “Delayed Sleep” and “Extended Time in Bed”. The “Reduced Time in Bed” and “Delayed Sleep” subgroups had more adverse sleep outcomes and psychological changes during the outbreak. The emergence of new sleep difficulties was independently associated with female sex, chronic illnesses, being employed, family responsibilities, earlier wake‐up times, higher stress levels, as well as heavier alcohol use and television exposure. The heterogeneity of sleep changes in response to the pandemic highlights the need for tailored interventions to address sleep problems. 相似文献
8.
9.
10.
Ziad Saad Derrek Hibar Maggie Fedgchin Vanina Popova Maura L Furey Jaskaran B Singh Hartmuth Kolb Wayne C Drevets Guang Chen 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(9):549
BackgroundAt ketamine and esketamine doses at which antidepressant doses are achieved, these agents are relatively selective, noncompetitive, N-methyl-D-aspartate receptor antagonists. However, at substantially higher doses, ketamine has shown mu-opioid receptor (MOR–gene symbol: OPRM1) agonist effects. Preliminary clinical studies showed conflicting results on whether naltrexone, a MOR antagonist, blocks the antidepressant action of ketamine. We examined drug-induced or endogenous MOR involvement in the antidepressant and dissociative responses to esketamine by assessing the effects of a functional single nucleotide polymorphism rs1799971 (A118G) of OPRM1, which is known to alter MOR agonist-mediated responses.MethodsParticipants with treatment-resistant depression from 2 phase III, double-blind, controlled trials of esketamine (or placebo) nasal spray plus an oral antidepressant were genotyped for rs1799971. Participants received the experimental agents twice weekly for 4 weeks. Antidepressant responses were rated using the change in Montgomery–Åsberg Depression Rating Scale (MADRS) score on days 2 and 28 post-dose initiation, and dissociative side effects were assessed using the Clinician-Administered Dissociative-States Scale at 40 minutes post-dose on days 1 and 25.ResultsIn the esketamine + antidepressant arm, no significant genotype effect of single nucleotide polymorphism rs1799971 (A118G) on MADRS score reductions was detected on either day 2 or 28. By contrast, in the antidepressant + placebo arm, there was a significant genotype effect on MADRS score reductions on day 2 and a nonsignificant trend on day 28 towards an improvement in depression symptoms in G-allele carriers. No significant genotype effects on dissociative responses were detected.ConclusionsVariation in rs1799971 (A118G) did not affect the antidepressant response to esketamine + antidepressant. Antidepressant response to antidepressant + placebo was increased in G-allele carriers, compatible with previous reports that release of endorphins/enkephalins may play a role in mediating placebo effect.Trial Registration and NCT02417064; NCT02418585www.clinicaltrials.gov 相似文献